UK price cuts feature in finalised price scheme
This article was originally published in Scrip
The UK pharmaceutical industry has reached agreement with the government on a new pharmaceutical pricing scheme (PPRS) with both sides of the negotiations expressing satisfaction with the outcome. Price cuts are not to be as deep or rapid as first expected and pharmaceutical companies launching innovative medicines will have greater flexibility where pricing is concerned.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.